Cardinal Health raises annual profit target

Cardinal Health (CAH.N) increased its fiscal year 2025 adjusted profit per share guidance to $8.15-$8.20, up from the previous $8.05-$8.15 range, driven by strong demand for specialty medicines and branded drugs. The updated forecast exceeds the analysts' consensus estimate of $8.13 per share. The company also issued a preliminary fiscal year 2026 adjusted profit per share forecast of $9.10-$9.30, aligning closely with the analysts' estimate of $9.12.

Analysis

Cardinal Health has upwardly revised its fiscal 2025 adjusted profit per share forecast to a range of $8.15 to $8.20, an increase from the previously guided $8.05 to $8.15. This improved outlook is attributed to sustained strong demand for costly specialty medicines and branded drugs within its pharmaceuticals division. The midpoint of the new FY25 guidance, $8.175, surpasses the LSEG analyst consensus estimate of $8.13 per share, signaling a positive development for the company's near-term earnings potential. Furthermore, Cardinal Health has issued a preliminary adjusted profit per share forecast for fiscal 2026, projecting $9.10 to $9.30, which aligns closely with the current analyst estimate of $9.12. This suggests management's confidence in continued growth, supported by the strong positive sentiment score of 0.75 for CAH.

Key Decisions for Investors

• Investors should view Cardinal Health's raised FY25 profit guidance, now exceeding analyst consensus, as a positive indicator of its operational strength and ability to capitalize on demand for high-value pharmaceuticals.
• The preliminary FY26 profit forecast, which is in line with current analyst expectations, suggests sustained earnings momentum; however, assess whether this longer-term outlook is already priced into the stock.
• Consider monitoring the pharmaceutical unit's performance, particularly the demand trends for specialty and branded drugs, as these are key drivers for achieving the revised and future profit targets.